Matt Krebs

A biopharma investor told me this morning: “This 👇 is what differentiates BioCentury Inc.” | Matt Krebs posted on the topic | LinkedIn A biopharma investor told me this morning: “This 👇 is what differentiates BioCentury Inc.” They were referring to our latest coverage on quantum computing, and why it matters now for biopharma lead...

www.linkedin.com/posts/mattkr...

🎭 “Somebody stop me!” 🎭 | Matt Krebs posted on the topic | LinkedIn 🎭 “Somebody stop me!” 🎭 --masked biologics, breaking past old toxicity limits with new clinical momentum Tierney Baum, PhD (BioCentury Inc.) unveils her latest analysis on how masking platforms are ...

www.linkedin.com/posts/mattkr...

🎡 Zoltar meets predictive pharmacology? | Matt Krebs 🎡 Zoltar meets predictive pharmacology? [Full disclosure -- BIG was one of my favorite movies growing up!] My colleague Tierney Baum, PhD talks to Syndeio Biosciences on their CNS drug development...

🎡 Zoltar meets predictive pharmacology?

www.linkedin.com/posts/mattkr...

This BioCentury Inc. | Matt Krebs This BioCentury Inc. data will surprise you? A look at private biopharma raising Seed and Series A rounds over past 9 years. https://lnkd.in/gcC-2nQZ

This BioCentury Inc. data will surprise you?

A look at private biopharma raising Seed and Series A rounds over past 9 years. www.linkedin.com/posts/mattkr...

Are you seeing a flurry of activity in endometriosis? | Matt Krebs Are you seeing a flurry of activity in endometriosis? Despite this miss by Organon, I’m hearing growing investor interest. A.k.a. Endometriosis is coming up more often on calls I’m on with VCs/CVCs, ...

Monty Python fans out here? www.linkedin.com/posts/mattkr...

👀 Looking to see who is translating science into startups? | Matt Krebs 👀 Looking to see who is translating science into startups? BioCentury Inc.’s Danielle Golovin, Ph.D. spotlights several stealth-to-stage stories, including cos like: 🔹 Arzanya 🔹 Capstan Therapeutics...

www.linkedin.com/posts/mattkr...

Looking to see who is translating science into startups?

BioCentury Inc.’s Danielle Golovin, Ph.D. spotlights several stealth-to-stage stories

$2.6B VC dispute threatening to sink stealth-mode biotechs? | Matt Krebs $2.6B VC dispute threatening to sink stealth-mode biotechs? BioCentury’s Steve Usdin and Paul Bonanos unpack Apple Tree’s clash with Dmitry Rybolovlev, and what it could mean for its portfolio and th...

$2.6B VC dispute threatening to sink stealth-mode biotechs?

BioCentury’s Steve Usdin and Paul Bonanos unpack Apple Tree’s clash with Dmitry Rybolovlev, and what it could mean for its portfolio and the broader biotech ecosystem.

📄 Full analysis 👇 👇 👇
www.linkedin.com/posts/mattkr...

PERSONAL NOTE: Any wiffleball fans out there? | Matt Krebs PERSONAL NOTE: Any wiffleball fans out there? Ever get a box of old photos that took you back to your childhood? Flood of memories poor in? Recently, I came across the pic of me and my bro (the pi...

Wiffleball anyone? www.linkedin.com/posts/mattkr...

👇👇👇 | Matt Krebs 👇👇👇

From my @biocentury.bsky.social colleague: www.linkedin.com/posts/mattkr...

One small step for cell surface targeting. One giant leap for solid tumor… | Matt Krebs One small step for cell surface targeting. One giant leap for solid tumor innovation... https://lnkd.in/g-Q4-Gs8 BioCentury Inc.'s Lauren Martz dives into the gory details of first-in-human trial...

One small step for cell surface targeting. One giant leap for solid tumor innovation...

www.linkedin.com/posts/mattkr...

#asco2025 #asco25 #bispecifics #immunooncology | Matt Krebs [ASCO]’ll Be Back... "Ahead of next week’s #ASCO2025 meeting, Merus N.V. is emerging as a standout with promising PII data from its EGFR x LGR5 bispecific antibody, petosemtamab. The candidate h...

[ASCO]’ll be back

www.linkedin.com/posts/mattkr...

🎤 EpCAM REVIVAL!

lnkd.in/gGmJaq8W

EpCAM is back on center stage. This time with conditionally activated ADCs, smarter bispecifics, and even CAR Ts?

lnkd.in/gGmJaq8W

#raredisease #biotechstrategy #biomarin | Matt Krebs Are you a biopharma C-suite exec or investor dissecting rare disease playbooks? Then this one's for you. BioMarin Pharmaceutical Inc. just made its 1st acquisition in 10+ yrs. The $270M price ...

Are you a biopharma C-suite exec or investor dissecting rare disease playbooks?

Then this one's for you.

www.linkedin.com/posts/mattkr...

How Boston Pharmaceuticals got a $1.2B deal for a liver disease drug. | Matt Krebs posted on the topic | LinkedIn 📉 How do you go from 15 scattered assets… to a $1B+ upfront deal? Boston Pharmaceuticals did exactly that. One big pivot => making liver disease its top priority. Now GSK is paying $1.2B upfr...

📉 How do you go from 15 scattered assets… to a $1B+ upfront deal?

www.linkedin.com/posts/mattkr...

Calling on Major League Baseball (MLB) fans. I'm curious. Who is your… | Matt Krebs Calling on Major League Baseball (MLB) fans. I'm curious. Who is your pick to be the HR leader for the 2025 season. Take the poll below. 👇 👇 👇 NOTE: As of May 16: • Aaron Judge (Yankees) – 1...

I'm curious. Who is your pick to be the HR leader for the 2025 season. Take the poll below. 👇 👇 👇

www.linkedin.com/posts/mattkr...

#aacr25 #proteindegrader #kras | Matt Krebs Is SMARCA2 the next KRAS moment for targeted protein degradation? Degraders are stepping in where SM have stalled? 📈 Lauren Martz dives into clinical and PC strategies across Prelude Therapeutics, ...

Is SMARCA2 the next KRAS moment for targeted protein degradation?

www.linkedin.com/posts/mattkr...

I post a survey about what kinda curry you may like... and BOOM. Thing explodes. LOL

Here's the link [LinkedIn]: www.linkedin.com/feed/update/...

🚨 New contender in the oral GLP-1 race 🚨

www.linkedin.com/posts/mattkr... (OPEN ACCESS)

Ascletis Pharma Inc. ($1672.HK) just dropped early PIb data showing up to 6.5% placebo-adjusted weight loss in obese patients after 4 weeks on ASC30.

By @biocentury.bsky.social's @stephenhansen.bsky.social

“Hey you guys!” – The Goonies

Looking for a roadmap for how to handle Tariffs?

BioCentury Inc.'s Simone Fishburn breaks down things you need to know in her latest report:

"Tariffs are here — sweating the SWOT analysis" www.linkedin.com/posts/mattkr...

PERSONAL NOTE: 🌱 Need a break from doom-scrolling? Planting and prompting been working for me! 💻

- 2 things that help me stay grounded (literally and digitally):

www.linkedin.com/posts/mattkr...

Twenty Lessons, read by John Lithgow | Peter Kolchinsky | 31 comments Be as courageous as you can. Do not obey in advance. Believe in truth. These are but three of 20 ways to fend off tyranny in our country and lives. Listen to… | 31 comments on LinkedIn

This is a pretty powerful piece! www.linkedin.com/posts/peterk...

☢️ Are you a RADIO[LIGAND]HEAD fan? PART II ☢️ Looks like Telix… | Matt Krebs ☢️ Are you a RADIO[LIGAND]HEAD fan? PART II ☢️ Looks like Telix Pharmaceuticals Limited’s end-to-end radiopharma strategy could pay off big time? This isn’t…

Any radiophamra & Radiohead fans out here on Bluesky?

If so, this one’s for you:
www.linkedin.com/posts/mattkr...

Drug Development Disco | LinkedIn Tune in this week to learn how access to expert curation uncovers hidden biomedical innovations, unlocking targets and technologies from around the world. Our guests this week: Dr. Karen Tkach Tuzman...

🔊 ATTENTION: Innovation Hunters 🔊

🎥 lnkd.in/gpjDuvDC 🎥

Missed the latest @BioCentury Inc. Drug Development Disco 🪩 🪩 🪩 ? No worries—watch the recording.

Open it up on a Pc. You can get full access to about 4 - 5 articles a month.

Warning. That’s how they got me. I blew threw my limit and got a subscription:)

His Death Was Interrupted, Just as He Had Planned Brendan Costello’s family was bracing for goodbyes. But he had one last wish.

His Death Was Interrupted, Just as He Had Planned. Brendan Costello’s family was bracing for goodbyes. But he had one last wish -- donating his organs, by @danbarry58.bsky.social www.nytimes.com/2025/03/16/n... #disability #transplant

Thank you @danbarry58.bsky.social from the @nytimes.com for the beautiful story.

His Death Was Interrupted, Just as He Had Planned Brendan Costello’s family was bracing for goodbyes. But he had one last wish.

I never truly understood the impact of organ donation until my cousin passed last month.

Story starts with a successful kidney transplant for a psychiatrist who has saved countless others suffering from depression

LI:
www.linkedin.com/posts/mattkr...
NYT:
www.nytimes.com/2025/03/16/n...

Chasing Amy? Nah... How about Chasing Amylin?

BioCentury dives into Roche’s $1.7B upfront bet on Zealand Pharma.

🔍 What’s in it for you?

1️⃣ Amylin is shaping up to be the next frontier in obesity drug development
2️⃣ Roche has skin in the game

Details: www.biocentury.com/article/6553...

Bispecifics overtake ADCs in China deals As Western biopharmas increasingly turned to Chinese biotechs to access antibody innovation in recent years, antibody-drug conjugates quickly came to domin...

This took a couple of folks by surprise:

"Bispecifics overtake ADCs in China deals"

Recent BioCentury Inc. Data Graphic report from Lauren Martz dives in.

Details and analysis here: www.biocentury.com/article/6552...

Great discussion of #biotech newco model at BioCentury's 4th East-West Biopharma Summit in Singapore, including leaders from Novo Holdings and Jeito, which just announced a newco with Singapore's Hummingbird last night.

www.Biocenturyeastwest.com